Bilateral Corneal Perforation in a Patient Under Anti-PD1 Therapy

Anaïs Ramaekers, Sandrine Aspeslagh, Nele De Brucker, Camille Van Mierlo, Marcel Ten Tusscher, Pieter-Paul Schauwvlieghe, Karolien Termote

Research output: Contribution to journalArticle

Abstract

ABSTRACT: Immune checkpoint inhibition has improved the clinical outcomes for numerous patients with cancer. However, the downside is a whole new spectrum of immune-related adverse events. We report a 68-year-old man with a history of nonsmall cell lung cancer presenting with a spontaneous corneal perforation in the right eye after 22 cycles of pembrolizumab. In addition, a chronic central nonhealing epithelial defect developed after performing a penetrating keratoplasty. Treatment with autologous serum drops resulted in complete healing of the corneal ulcer, where other conventional therapies had no effect. One month after reinitiating pembrolizumab therapy, our patient presented again with a corneal perforation in the fellow eye. This case describes relapsing sterile ulcerations associated with pembrolizumab use and presents an unexpected cure.

Original languageEnglish
Pages (from-to)245-247
Number of pages3
JournalCornea
Volume40
Issue number2
DOIs
Publication statusPublished - 1 Feb 2021

Bibliographical note

Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

Keywords

  • Bilateral Corneal Perforation
  • Anti-PD1 Therapy
  • cancer

Fingerprint Dive into the research topics of 'Bilateral Corneal Perforation in a Patient Under Anti-PD1 Therapy'. Together they form a unique fingerprint.

Cite this